Daiwa SB Investments’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
$1.5M Sell
5,220
-1,030
-16% -$298K 0.3% 55
2018
Q4
$1.64M Buy
6,250
+690
+12% +$190K 0.38% 53
2018
Q3
$1.52M Buy
5,560
+140
+3% +$36.3K 0.3% 61
2018
Q2
$1.29M Buy
5,420
+390
+8% +$90.3K 0.31% 64
2018
Q1
$1.1M Sell
5,030
-1,360
-21% -$319K 0.32% 61
2017
Q4
$1.44M Sell
6,390
-200
-3% -$42.6K 0.38% 36
2017
Q3
$1.25M Buy
6,590
+820
+14% +$156K 0.35% 42
2017
Q2
$1.09M Sell
5,770
-2,050
-26% -$368K 0.3% 45
2017
Q1
$1.29M Sell
7,820
-560
-7% -$89.1K 0.35% 40
2016
Q4
$1.21M Sell
8,380
-120
-1% -$16.1K 0.32% 44
2016
Q3
$1.06M Sell
8,500
-3,190
-27% -$412K 0.28% 52
2016
Q2
$1.54M Sell
11,690
-4,280
-27% -$586K 0.44% 37
2016
Q1
$2.22M Sell
15,970
-2,840
-15% -$380K 0.56% 34
2015
Q4
$2.62M Sell
18,810
-3,044
-14% -$419K 0.61% 38
2015
Q3
$3.06M Buy
+21,854
New +$3.28M 0.7% 39

Other funds holding ELV

Daiwa SB Investments's ELV Position: Q1 2019 in Review

Daiwa SB Investments reduced its Elevance Health (ELV) stake by 16% in Q1 2019, selling an estimated $298K and leaving 5,220 shares worth $1.5M. The position accounts for 0.3% of the portfolio, ranked #55.

Daiwa SB Investments first reported a position in ELV in Q3 2015 and has held it in 15 quarters since. The position peaked at $3.06M in Q3 2015. 1,074 funds tracked by Wall St. Rank hold ELV as of Q1 2019.

  • Daiwa SB Investments held 5,220 shares of Elevance Health worth $1.5M as of Q1 2019.
  • Daiwa SB Investments sold 1,030 Elevance Health shares in Q1 2019, an estimated $298K.
  • Elevance Health made up 0.3% of Daiwa SB Investments's portfolio in Q1 2019, its #55 holding.
  • Daiwa SB Investments first reported a position in Elevance Health in Q3 2015 and has held it in 15 quarters since.
  • Daiwa SB Investments's Elevance Health position peaked at $3.06M in Q3 2015.
  • 1,074 funds tracked by Wall St. Rank held Elevance Health as of Q1 2019.

Based on Daiwa SB Investments's 13F filing for Q1 2019, filed 18 Apr 2019.